Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand
Published
Last week, Novavax Inc NVAX received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in individuals aged 12 and older. Wall Street analysts are optimistic about Novavax's prospects despite its vaccine's release delay compared to Pfizer Inc PFE and…
#novavaxincnvax #fda #novavax #pfizerincpfe #modernainc #jefferies #rogersong #nvax